Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring and translating the functionality gut microbiome changes may have on improving gut health and its therapeutic potential to treat/prevent a variety of gastrointestinal diseases.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 1880 Century Park East #1000, Los Angeles,ca 90067,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.ritterpharma.com
- HQ
- Los Angeles, CA
Ritter Pharmaceuticals, Inc. Questions
Ritter Pharmaceuticals, Inc.'s website is http://www.ritterpharma.com
Ritter Pharmaceuticals, Inc.'s LinkedIn profile is https://www.linkedin.com/company/ritterpharma
Ritter Pharmaceuticals, Inc. has
6 employees.
View email and phone details for 6
employees at Ritter Pharmaceuticals, Inc..
Ritter Pharmaceuticals, Inc.'s industry is
Pharmaceutical Manufacturing
Ritter Pharmaceuticals, Inc.'s top competitors are
Ritter Gmbh,
Metabiomics,
Anacor Pharmaceuticals,
Mirum Pharmaceuticals, Inc.,
Olipop Pbc,
Ritter Center,
Ritter España,
Satsuma Pharmaceuticals, Inc.,
Docbot,
Napo Pharmaceuticals, Inc..
Ritter Pharmaceuticals, Inc.'s categories are Pharmaceutical Manufacturing
Ritter Pharmaceuticals, Inc.'s founding year is 2004
